Evidence map›Paper›PMID 30539499›Full record

ArticleJournal of physiology and biochemistry2019

Anti-obesity effects of kaempferol by inhibiting adipogenesis and increasing lipolysis in 3T3-L1 cells.

D Torres-Villarreal, A Camacho, H Castro, R Ortiz-Lopez, A L de la Garza

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of physiology and biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Advances in Research onMolecules (Basel, Switzerland) · 2026
    Review
  5. Article
  6. Article
  7. Hepatoprotective Effect of Kaempferol-A Review.Molecules (Basel, Switzerland) · 2025
    Review
  8. Molecules (Basel, Switzerland) · 2025
    Review
  9. Article
  10. Frontiers in pharmacology · 2025
    Article
  11. Journal of microbiology and biotechnology · 2024
    Article
  12. Article
  13. Article
  14. Flavonoids, gut microbiota, and host lipid metabolism.Engineering in life sciences · 2024
    Review
  15. Review
  16. Review
  17. Mechanisms of Action ofDrug design, development and therapy · 2024
    Article
  18. Evaluation of the anti-obesity effect ofFrontiers in pharmacology · 2024
    Article
  19. Article
  20. Journal of traditional and complementary medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

D Torres-VillarrealFacultad de Salud Pública y Nutrición, Centro de Investigación en Nutrición y Salud Pública, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico.
A CamachoFacultad de Medicna, Departamento de Bioquímica y Medicina Molecular, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico.
H CastroFacultad de Salud Pública y Nutrición, Centro de Investigación en Nutrición y Salud Pública, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico.
R Ortiz-LopezTecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, Mexico.
A L de la GarzaFacultad de Salud Pública y Nutrición, Centro de Investigación en Nutrición y Salud Pública, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico. ana.dlgarzah@uanl.mx.
Universidad Autónoma de Nuevo León · MXTecnológico de Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaempferol is a natural flavonoid widely found in fruits, vegetables, and tea. Kaempferol possesses beneficial biological properties such as anti-inflammatory and antioxidant activities. Positive energy balance during obesity correlates with a pro-inflammatory chronic state. In this context, we hypothesized that kaempferol might promote anti-obesity effects by modulating adipogenesis and lipolytic pathways. Adipocyte viability at 24, 48, and 72 h was measured by an ATP-based assay. Pre-adipocytes (day 0) or mature adipocytes (day 12) were treated with 60 μM kaempferol until day 21 to evaluate its potential anti-adipogenic and lipolytic effect, respectively. Total lipid accumulation was assessed using Oil Red O staining assay. Gene expression was measured by RT-qPCR to evaluate the effect of kaempferol on adipogenesis and lipolysis gene expression. Our results showed a dose-dependent effect of kaempferol treatment on cell viability promoting cell death at higher than 60 μM concentration. Pre-adipocytes stimulation by 60 μM kaempferol resulted in 62% adipogenesis inhibition whereas in mature adipocytes, it reduced 39% intracellular lipid accumulation. Also, 60 μM kaempferol treatment decreased Cebpa mRNA expression when compared to control cells. In contrast, Pnpla2 and Lipe gene expression were upregulated in 3T3-L1 cells incubated with 60 μM kaempferol. In summary, our results showed that kaempferol modulates adipogenic differentiation in 3T3-L1 cells by promoting downregulation of Cebpa gene expression and decreasing lipid accumulation in mature adipocytes by its positive effects on Pnpla2 and Lipe mRNA levels. Kaempferol might display an anti-obesity effect.

Indexed as

3T3-L1 CellsAcyltransferasesAdipocytesAdipogenesisAnimalsAnti-Obesity AgentsAzo CompoundsCCAAT-Enhancer-Binding ProteinsCell DifferentiationCell SurvivalDose-Response Relationship, DrugGene Expression RegulationKaempferolsLipaseLipolysisMiceAcyltransferasesAnti-Obesity AgentsAzo CompoundsCCAAT-Enhancer-Binding ProteinsCEBPA protein, mousekaempferolKaempferolsLipaseoil red OPNPLA2 protein, mouseRNA, MessengerAdipogenesisFlavonoidsKaempferolLipolysisObesity

Identifiers

PMID30539499
OpenAlexW2905385675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.